Nathan Robison, MD, presents a case of a 14-year-old male with a progressive hypothalamic low-grade glioma whose newly identified KIAA1549::BRAF fusion informs consideration of next-line treatment options after years of relative stability.
Matthew Cascio, DO, reviews second-line treatment for a case of BRAF V600E-mutated recurrent or refractory pediatric low-grade glioma, following initial combination treatment with dabrafenib and trametinib.
Sameer Farouk Sait, MBBS, reviews a case of focal BRAF fusion–positive pediatric low-grade brainstem glioma that initially responded to chemotherapy but later recurred, prompting molecularly guided targeted therapy complicated by treatment-related toxicities.
Nicholas Whipple, MD, MPH, reviews a case of extensive pediatric optic pathway glioma with progression on chemotherapy and MEK inhibition, highlighting the role of molecular testing, BRAF/MEK-targeted therapy, and considerations for treatment selection at recurrence.
Mohamed Shebl Abdelbaki, MD, presents a case of a 9-year-old girl with unresectable BRAF V600E–mutant thalamic pilocytic astrocytoma who experienced severe pyrexia and treatment intolerance on dabrafenib plus trametinib, prompting consideration of alternative therapeutic options.
Matthew Cascio, DO, presents a case of a 3-month-old infant with a bilateral optic pathway glioma that progressed on frontline carboplatin and was subsequently found to be a BRAF V600E–mutated pilocytic astrocytoma.
Lindsey Hoffman, DO, presents a case of a 10-year-old girl with an unresectable BRAF V600E–mutated brainstem ganglioglioma causing obstructive hydrocephalus and visual symptoms, highlighting treatment considerations when further surgical resection is not feasible.
Ashley Margol, MD, MS, presents a case of a 7-year-old girl with a KIAA1549-BRAF fusion–positive pilocytic astrocytoma that remained stable during and after carboplatin-vincristine therapy before progressing nearly 2 years later with new neurologic symptoms requiring additional treatment.
Mohamed Shebl Abdelbaki, MD, presents a case of a 1-year-old boy with a KIAA1549-BRAF fusion–positive brainstem ganglioglioma that demonstrated significant radiographic progression after 3 months of carboplatin and vincristine therapy, prompting consideration of alternative treatment strategies.
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
